SAMRAT PHARMACHEM Financial Statement Analysis
|
||
The Revenues of SAMRAT PHARMACHEM have decreased by -9.36% YoY .
The Earnings Per Share (EPS) of SAMRAT PHARMACHEM has decreased by -87.00 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
SAMRAT PHARMACHEM Last 5 Annual Financial Results
[BOM: 530125]
Standalone | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹282 Cr | ₹311 Cr | ₹222 Cr | ₹179 Cr | ₹137 Cr |
Expenses | ₹279 Cr | ₹287 Cr | ₹198 Cr | ₹170 Cr | ₹131 Cr |
Operating Profit (Excl OI) | ₹2.47 Cr | ₹24 Cr | ₹24 Cr | ₹8.67 Cr | ₹6.63 Cr |
Other Income | ₹1.39 Cr | ₹0.48 Cr | ₹0.63 Cr | ₹0.46 Cr | ₹0.57 Cr |
Interest | ₹0.69 Cr | ₹1.23 Cr | ₹0.68 Cr | ₹1.28 Cr | ₹0.98 Cr |
Depreciation | ₹0.65 Cr | ₹0.64 Cr | ₹0.60 Cr | ₹0.49 Cr | ₹0.43 Cr |
Profit Before Tax | ₹2.52 Cr | ₹23 Cr | ₹24 Cr | ₹7.34 Cr | ₹5.79 Cr |
Profit After Tax | ₹2.16 Cr | ₹17 Cr | ₹17 Cr | ₹5.33 Cr | ₹4.24 Cr |
Earnings Per Share (Rs) | ₹7.00 | ₹53.83 | ₹55.62 | ₹17.26 | ₹13.71 |
PAT Margin (%) | 0.77 | 5.35 | 7.75 | 2.61 | 2.70 |
ROE(%) | 3.38 | 30.25 | 44.95 | 19.77 | 19.10 |
ROCE(%) | 4.13 | 34.91 | 52.33 | 23.90 | 22.43 |
Total Debt/Equity(x) | 0.13 | 0.30 | 0.16 | 0.30 | 0.39 |
Key Financials |
||
Market Cap | : | ₹ 116.5 Cr |
Revenue (TTM) | : | ₹ 295.4 Cr |
Net Profit(TTM) | : | ₹ 6.5 Cr |
EPS (TTM) | : | ₹ 20.9 |
P/E (TTM) | : | 18.0 |
Industry Peers & Returns | 1W | 1M | 1Y |
SAMRAT PHARMACHEM | -10.8% | -15.4% | 9.8% |
SUN PHARMACEUTICAL INDUSTRIES | 1% | 4.6% | 47.5% |
CIPLA | -1.1% | -0.3% | 20.7% |
DR REDDYS LABORATORIES | 2.2% | 12.1% | 21.6% |
ZYDUS LIFESCIENCES | -2.7% | 0.8% | 43.8% |
DIVIS LABORATORIES | 1% | -3.2% | 59.3% |
MANKIND PHARMA | 0.8% | 12.8% | 52.4% |
TORRENT PHARMACEUTICALS | -1.5% | 5.9% | 55% |
LUPIN | 0.9% | 7.2% | 72.7% |
SAMRAT PHARMACHEM Revenues
[BOM: 530125]
Y-o-Y | -9.36 % |
5 Yr CAGR | 19.64 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹282 Cr | -9.36 | |
Mar2023 | ₹311 Cr | 40.09 | |
Mar2022 | ₹222 Cr | 23.87 | |
Mar2021 | ₹179 Cr | 30.24 | |
Mar2020 | ₹137 Cr | - |
SAMRAT PHARMACHEM Operating Profit
[BOM: 530125]
Y-o-Y | -89.68 % |
5 Yr CAGR | -21.87 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹2.47 Cr | -89.68 | |
Mar2023 | ₹24 Cr | -1.28 | |
Mar2022 | ₹24 Cr | 179.61 | |
Mar2021 | ₹8.67 Cr | 30.76 | |
Mar2020 | ₹6.63 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -88.57 % |
5 Yr CAGR | -34.63 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 0.88% | -88.57 | |
Mar2023 | 7.7% | -29.55 | |
Mar2022 | 10.93% | 125.83 | |
Mar2021 | 4.84% | 0.41 | |
Mar2020 | 4.82% | - |
SAMRAT PHARMACHEM Profit After Tax
[BOM: 530125]
Y-o-Y | -86.99 % |
5 Yr CAGR | -15.47 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹2.16 Cr | -86.99 | |
Mar2023 | ₹17 Cr | -3.22 | |
Mar2022 | ₹17 Cr | 222.24 | |
Mar2021 | ₹5.33 Cr | 25.87 | |
Mar2020 | ₹4.24 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -85.61 % |
5 Yr CAGR | -26.92 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 0.77 % | -85.61 | |
Mar2023 | 5.35 % | -30.97 | |
Mar2022 | 7.75 % | 196.93 | |
Mar2021 | 2.61 % | -3.33 | |
Mar2020 | 2.7 % | - |
SAMRAT PHARMACHEM Earnings Per Share (EPS)
[BOM: 530125]
Y-o-Y | -87.00 % |
5 Yr CAGR | -15.47 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹7.00 | -87.00 | |
Mar2023 | ₹54 | -3.22 | |
Mar2022 | ₹56 | 222.25 | |
Mar2021 | ₹17 | 25.89 | |
Mar2020 | ₹14 | - |
SAMRAT PHARMACHEM Return on Capital Employed (ROCE)
[BOM: 530125]
Y-o-Y | -88.17 % |
5 Yr CAGR | -34.49 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 4.13% | -88.17 | |
Mar2023 | 34.91% | -33.29 | |
Mar2022 | 52.33% | 118.95 | |
Mar2021 | 23.9% | 6.55 | |
Mar2020 | 22.43% | - |
SAMRAT PHARMACHEM Share Price vs Sensex
Current Share Price | : | ₹375.7 |
Current MarketCap | : | ₹ 116.5 Cr |
Updated EOD on | : | Dec 26,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SAMRAT PHARMACHEM | -10.8% |
-15.4% |
9.8% |
SENSEX | -2.1% |
-2% |
11.3% |
SAMRAT PHARMACHEM related INDICES
You may also like the below Video Courses
FAQ about SAMRAT PHARMACHEM Financials
How the annual revenues of SAMRAT PHARMACHEM have changed ?
The Revenues of SAMRAT PHARMACHEM have decreased by -9.36% YoY .
How the Earnings per Share (EPS) of SAMRAT PHARMACHEM have changed?
The Earnings Per Share (EPS) of SAMRAT PHARMACHEM has decreased by -87.00 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs